ProfileGDS5678 / 1451712_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 18% 28% 17% 16% 17% 19% 17% 17% 17% 19% 21% 17% 17% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4549918
GSM967853U87-EV human glioblastoma xenograft - Control 22.6399228
GSM967854U87-EV human glioblastoma xenograft - Control 32.4204717
GSM967855U87-EV human glioblastoma xenograft - Control 42.3484816
GSM967856U87-EV human glioblastoma xenograft - Control 52.3688317
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5058519
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4363417
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4025417
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3866917
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4381519
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4929121
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3952517
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4203917
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8105436